These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34170371)

  • 21. Dialysis vintage and cardiovascular injury as factors influencing long-term survival in peritoneal dialysis and hemodialysis.
    Hoppe K; Schwermer K; Olewicz-Gawlik A; Klysz P; Kawka A; Baum E; Sikorska D; Ścigacz K; Roszak M; Lindholm B; Pawlaczyk K; Oko A
    Adv Clin Exp Med; 2017; 26(2):251-258. PubMed ID: 28791842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure.
    Franke S; Lehmann G; Abendroth K; Hein G; Stein G
    Eur J Med Res; 1998 Feb; 3(1-2):81-8. PubMed ID: 9512973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of serum galectin-3 levels with mortality and cardiovascular disease outcomes in hemodialysis patients: a systematic review and dose-response meta-analysis.
    Bellos I; Marinaki S; Lagiou P; Benetou V
    Int Urol Nephrol; 2024 Aug; 56(8):2755-2767. PubMed ID: 38519721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study.
    Trippel TD; Mende M; Düngen HD; Hashemi D; Petutschnigg J; Nolte K; Herrmann-Lingen C; Binder L; Hasenfuss G; Pieske B; Wachter R; Edelmann F
    ESC Heart Fail; 2021 Apr; 8(2):829-841. PubMed ID: 33566456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis.
    Lebedev DA; Lyasnikova EA; Vasilyeva EY; Babenko AY; Shlyakhto EV
    J Diabetes Res; 2020; 2020():6976153. PubMed ID: 33224989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum versus Imaging Biomarkers in Friedreich Ataxia to Indicate Left Ventricular Remodeling and Outcomes.
    Mehta N; Chacko P; Jin J; Tran T; Prior TW; He X; Agarwal G; Raman SV
    Tex Heart Inst J; 2016 Aug; 43(4):305-10. PubMed ID: 27547137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus.
    Lebedev DA; Lyasnikova EA; Vasilyeva EY; Likhonosov NP; Sitnikova MY; Babenko AY
    J Diabetes Res; 2021; 2021():9589185. PubMed ID: 34778465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of galectin-3 in chronic kidney disease patients: a systematic review and meta-analysis.
    Zhang T; Cao S; Yang H; Li J
    Int Urol Nephrol; 2019 Jun; 51(6):1005-1011. PubMed ID: 30963453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can be galectin-3 a novel marker in determining mortality in hemodialysis patients?
    Ozkan G; Ulusoy S; Menteşe A; Guvercin B; Karahan SC; Yavuz A; Altay DU; Ocal M
    Clin Biochem; 2015 Aug; 48(12):768-73. PubMed ID: 25977067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationships between circulating galectin-3, extracellular matrix fibrosis and outcomes in dilated cardiomyopathy.
    Rubiś P; Holcman K; Dziewięcka E; Wiśniowska-Śmiałek S; Karabinowska A; Szymonowicz M; Khachatryan L; Wypasek E; Garlitski A; Gackowski A; Podolec P
    Adv Clin Exp Med; 2021 Mar; 30(3):245-253. PubMed ID: 33754503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists.
    Koukoui F; Desmoulin F; Galinier M; Barutaut M; Caubère C; Evaristi MF; Murat G; De Boer R; Berry M; Smih F; Rouet P
    PLoS One; 2015; 10(3):e0119160. PubMed ID: 25786035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac biomarkers are influenced by dialysis characteristics.
    Sommerer C; Heckele S; Schwenger V; Katus HA; Giannitsis E; Zeier M
    Clin Nephrol; 2007 Dec; 68(6):392-400. PubMed ID: 18184522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intra-cardiac and peripheral levels of biochemical markers of fibrosis in patients undergoing catheter ablation for atrial fibrillation.
    Begg GA; Karim R; Oesterlein T; Graham LN; Hogarth AJ; Page SP; Pepper CB; Rhode K; Lip GYH; Holden AV; Plein S; Tayebjee MH
    Europace; 2017 Dec; 19(12):1944-1950. PubMed ID: 28339804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; Adourian A; Böhm M; van Veldhuisen DJ; Komajda M; Cleland JG; Wikstrand J; McMurray JJ; Aukrust P;
    Eur Heart J; 2012 Sep; 33(18):2290-6. PubMed ID: 22513778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure.
    Nymo SH; Aukrust P; Kjekshus J; McMurray JJ; Cleland JG; Wikstrand J; Muntendam P; Wienhues-Thelen U; Latini R; Askevold ET; Gravning J; Dahl CP; Broch K; Yndestad A; Gullestad L; Ueland T;
    JACC Heart Fail; 2017 Apr; 5(4):256-264. PubMed ID: 28359413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Galectin-3 is linked to peripheral artery disease severity, and urinary excretion is associated with long-term mortality.
    Ursli M; Zierfuss B; Grigassy T; Pesau G; Koppensteiner R; Schernthaner GH; Höbaus C
    Atherosclerosis; 2022 Jan; 341():7-12. PubMed ID: 34929561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased procollagen type I C-terminal peptide levels indicate diastolic dysfunction in end-stage renal disease patients undergoing maintenance dialysis therapy.
    Su CT; Liu YW; Lin JW; Chen SI; Yang CS; Chen JH; Hung KY; Tsai WC; Huang JW
    J Am Soc Echocardiogr; 2012 Aug; 25(8):895-901. PubMed ID: 22658561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients.
    Yao Y; Feng L; Sun Y; Wang S; Sun J; Hu B
    BMC Cardiovasc Disord; 2021 May; 21(1):264. PubMed ID: 34049488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.
    Wang CH; Yang NI; Liu MH; Hsu KH; Kuo LT
    Cardiol J; 2016; 23(5):563-572. PubMed ID: 27515479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.